Guggenheim Reiterates Buy Rating on Biogen (BIIB) following Apellis deal
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $246.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "Today, BIIB ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
